Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | MGMT | P16455 | 1/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.39 |
| ▸ | PDE4A | P27815 | 5/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874737 | 0.81 | ADORA2A (0.56) | ADORA2BADORA3PNPDPP4ADORA2A | |
| SCHEMBL1047660 | 0.81 | PNP (0.45) | ADORA2BCDK2PNPDPP4ADORA2A | |
| SCHEMBL28071828 | 0.81 | PNP (0.45) | ADORA2BMGMTPNPDPP4ADORA2A | |
| SCHEMBL667797 | 0.78 | PDE4A (0.60) | ADORA2BADORA3ADORA2APDE4APDE4B | |
| SCHEMBL27842808 | 0.78 | PDE4A (0.53) | ADORA2BPNPDPP4ADORA2APDE4A | |
| SCHEMBL669007 | 0.78 | ADORA2B (0.61) | ADORA2BADORA3CDK1CCNB1MGMT | |
| SCHEMBL3671339 | 0.78 | DPP4 (0.44) | ADORA2BADORA3PNPDPP4ADORA2A | |
| SCHEMBL28305222 | 0.78 | PDE4A (0.56) | ADORA2BADORA3PNPDPP4ADORA2A | |
| SCHEMBL2343362 | 0.77 | ADORA2A (0.44) | ADORA2BCDK1CCNB1MGMTCCNA2 | |
| SCHEMBL5504400 | 0.77 | ADORA2A (0.59) | ADORA2BCDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799524-B2 | Substrates for O6-alkylguanina-DNA alkyltransferase | Ecole Polytechnique Ferdeale de Lausanne (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20060024775-A1 | Substrates for o6-alkylguanina-dna alkyltransferase | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL). (CH) | 2006-02-02 | — | — | US | disclosed |
| CN-1720332-A | O6Substrates for -alkylguanine-DNA alkyltransferases | ECOLE POLYTECH (CH) | 2006-01-11 | — | — | CN | disclosed |
| EP-1017394-B1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER REC TECH LTD (GB) | 2005-12-07 | — | — | EP | disclosed |
| EP-1546371-A1 | SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031405-A1 | SUBSTRATES FOR O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2004-04-15 | — | — | WO | disclosed |
| US-6303618-B1 | ADMINISTERING PURINE COMPOUND WHICH INHIBITS CYCLIC DEPENDENT KINASE ACTIVITY FOR THERAPY OF TUMOR OR OTHER CELL PROLIFERATION DISORDER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| EP-1017394-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999002162-A9 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RES CAMPAIGN TECH (GB) | 1999-07-29 | — | — | WO | disclosed |
| WO-1999002162-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024775-A1 | Substrates for o6-alkylguanina-dna alkyltransferase | AGT, OGG1, NUDT1 | ADORA2B 2972/4885ADORA3 1783/4885CDK1 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.